A leading obesity doctor has said a new trial of weight loss drugs Mounjaro and Wegovy may lead advertisers to reconsider their prices.
Professor Naveed Sattar, an honorary consultant in metabolic health at Glasgow University, also told The Herald he hopes the recent head-to-head trial of two major weight loss drugs will lead to more people being able to access this type of medication via the NHS instead of privately.
His comments come after the first head-to-head trial of two weight-loss drugs has shown Mounjaro is more effective than its rival Wegovy.
Both drugs make you feel full so you eat less and instead burn fat stored in the body as they mimic a hormone released by the body after a meal.
The findings, published in the New England Journal of Medicine, showed that 32% of people lost a quarter of their body weight on Mounjaro compared to 16% on Wegovy after 72 weeks of treatment.
The research also found that women tended to lose more weight than men and those on Mounjaro had better blood pressure, blood sugar and cholesterol levels.
Professor Sattar, who leads the UK Government’s Obesity Healthcare Goals Programme, said this trial is likely to encourage Mounjaro sales.
Naveed Sattar, a Professor of Cardiometabolic Medicine and Honorary Consultant at Glasgow University (Image: UNIVERSITY OF GLASGOW PHOTOGRAPHIC UNIT) He said: “The reality will be that if the drugs are broadly similar in price people are going to go for the one that gives you bigger weight loss.
“This may end up leading to advertisers reconsidering their prices which could potentially be good for the NHS.
“People are voting with their money by buying these drugs, mostly in the private market.”
READ MORE:
- Weight-loss jab Mounjaro helps people shed much more weight than rival – study
- Weight loss injections may have an anti-cancer effect ‘beyond weight loss’
The Scottish Health Survey for 2023 found almost a third of adults (32%) were living with obesity, up from 24% in 2003 to the highest level since the survey started.
Wegovy (semalglutide) and Mounjaro (tirzepatide) are the first weight loss drugs of their kind licenced in the UK, and Professor Sattar expects more types of these drugs to appear on the market soon.
“These are the first two that are licenced but hopefully in the next three or four years we have another two or three to come into the market as well.
“I’m hoping in about five or ten years, we will have a range of drugs that give different degrees of weight loss but at a different range of costs that people can afford, including, perhaps, oral tablets as well.
“One is due to reach the market next year which would be great,” Professor Sattar added.
Professor Sattar said, at the moment, the cost of the drugs is creating space for criminal activity.
“One of the issues is because the drugs are expensive, it's become a bit of a market for crime, for profiteering and so that’s the thing we have to eradicate to allow people to buy them safely,” Professor Sattar said.
Professor Sattar said improvements are being made to how these drugs are marketed online and he is seeing a “tightening up” of restrictions of who can purchase the drugs through online pharmacies.
Naveed Sattar is a professor of Cardiometabolic Medicine and an Honorary Consultant at Glasgow University. You can read some of his work here.
However, he would like to see their availability widened out and more people gain access to them via the NHS.
“But ultimately, the ideal scenario would be to have the NHS to prescribe it to anyone who can potentially benefit but simply can’t afford it.
“At the moment, the NHS helps with people who really do need it. People with very high levels of obesity, lots of co-mobility and lots of disease but hopefully if the costs come down we can widen the net,” Professor Sattar said.
He added: “None of us want to have a world where the only way we can tackle obesity or one of the major ways that many people go towards is medication."
Asked if he would like to see the NHS offer weight loss drugs to more patients, Professor Sattar said: “100%.
"Of course I would, but the costs of the drugs are such that we can’t afford to do that at this moment in time but what we need to do is work out a way that the costs start to come down on the drugs.
“At the moment, the NHS is partly fire-fighting lots of people in their 60s, 70s and 80s living with five or six conditions on 20 drugs who are carrying a bit excess weight and maybe more that half of their conditions are linked to their excess weight.”
The recent trial, which was paid for by Eli Lilly, the manufacturer of Mounjaro, involved 750 obese people, with an average weight of 113kg (nearly 18 stone).
However, Professor Sattar said the process of this trial was “completely robust” and he is not concerned that the results were in any way manufactured.
“The final results looked exactly like what we predicted based on previous trials,” he added.
“We already knew that tirzepatide (Mounjaro) lowered weight by about 20% and semaglutide (Wegovy) by about 15% at the higher doses but to do a head-to-head trial shows exactly that is definitely the case.”
The trial also found that the side effects of both drugs were largely no different from one another.
“That means you are getting extra weight loss but without having more side effects,” he said.
Professor Sattar said both drugs have led to a break-through in weight loss medicine.
“We didn’t have drugs that could get you anywhere near 10% [in weight reduction] and also all these other benefits till five years ago. Now, we’ve got two.”
Currently, Wegovy, has more evidence of being beneficial for other health issues such as heart attacks and kidney disease while the equivalent trails for Mounjaro are yet to be completed.
A 13,000 patient-led study is expected to show whether Mounjaro has the same effects by the end of this year.
“But that doesn’t seem to be affecting the market. What people seem to be wanting is weight loss,” he added.
Professor Sattar said there is currently a “substantial” amount of research around these weight loss drugs being carried out which have been on the market for nearly ten years now.
He said lower doses of the drugs began to see use back in 2007 and higher doses began being administered in the last five years.
“So far, up to about four or five years, they look safe and it looks like the benefits are sustained in terms of weight loss.
"What we don’t know is what happens after ten years or 15 years. These are the kinds of issues that we really need to try and work out.
Professor Sattar has said modern living has “pushed calories everywhere” which makes it very hard for most people to resist.
“A lot of people have now got this food noise with lots of food available and so they overeat. So it’s hard unless you change the environment fundamentally where you have less cars, more bikes, far less fast food, far better healthier foods, far less calories, we’re going to have this problem forever.”
Share